CD70 is a novel therapeutic target for EGFR mutant NSCLC with acquired, EMT-associated EGFR TKI resistance

被引：0

作者：

Nilsson, Monique B. ^{[1
]}

Yang, Yan ^{[1
]}

Patel, Sonia ^{[1
]}

Heeke, Simon ^{[1
]}

Le, Xiuning ^{[1
]}

Aruguman, Thiru ^{[1
]}

Robichaux, Jacqulyne ^{[1
]}

Yu, Xiaoxing ^{[1
]}

Poteete, Alissa ^{[1
]}

Ren, Xiaoyang ^{[1
]}

Diao, Lixia ^{[1
]}

Shen, Li ^{[1
]}

Wang, Qi ^{[1
]}

Zhang, Fahao ^{[1
]}

Clemente, Leticia Campos ^{[1
]}

Soto, Luisa Solis ^{[1
]}

Shi, Chunhua ^{[1
]}

Tran, Hai ^{[1
]}

Bock, Jason ^{[1
]}

Wang, Jing ^{[1
]}

Wistuba, Ignacio I. ^{[1
]}

Minna, John D. ^{[2
]}

Heymach, John V. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Univ Texas SouthWestern Med Ctr, Dallas, TX USA

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1827

引用

页数：1

共 50 条

[41] Is CD73 Expression a Druggable Mechanism of Resistance in EGFR-TKI-Treated EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)?
Eide, I. J.
Dyrbekk, A. P.
Helland, A.
Ekman, S.
Koivunen, J.
Cicenas, S.
Gronberg, B.
Bisha, I.
Haberichter, T.
Lakis, S.
Chan, J.
Lewis, A.
Martin, P.
Cooper, Z.
Brustugun, O. T.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1154 - S1154
[42] Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC
Peters, T. L.
Patil, T.
Le, A. T.
Davies, K. D.
Brzeskiewicz, P. M.
Nijmeh, H.
Bao, L.
Camidge, D. R.
Aisner, D. L.
Doebele, R. C.
NPJ PRECISION ONCOLOGY, 2021, 5 (01)
[43] Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC
T. L. Peters
T. Patil
A. T. Le
K. D. Davies
P. M. Brzeskiewicz
H. Nijmeh
L. Bao
D. R. Camidge
D. L. Aisner
R. C. Doebele
npj Precision Oncology, 5
[44] Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
Myall, Nathaniel J.
Whisenant, Jennifer G.
Neal, Joel W.
Iams, Wade T.
Reckamp, Karen L.
York, Sally
Berry, Lynne D.
Shyr, Yu
Horn, Leora
Wakelee, Heather A.
Padda, Sukhmani K.
JTO CLINICAL AND RESEARCH REPORTS, 2025, 6 (02):
[45] Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation
Izumi, Hiroto
Kanda, Rina
Murakami, Yuichi
Morimoto, Yasuo
Ono, Mayumi
EUROPEAN RESPIRATORY JOURNAL, 2014, 44
[46] Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation
Izumi, Hiroto
Kanda, Rina
Murakami, Yuichi
Morimoto, Yasuo
Ono, Mayumi
EUROPEAN RESPIRATORY JOURNAL, 2014, 44
[47] Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC
Lee, Eun Ji
Oh, Seung Yeon
Lee, You Won
Ju Young, Kim
Kim, Min-Je
Kim, Tae Ho
Lee, Jii Bum
Hong, Min Hee
Lim, Sun Min
Baum, Anke
Woelflingseder, Lydia
Engelhardt, Harald
Petronczki, Mark
Solca, Flavio
Yun, Mi Ran
Cho, Byoung Chul
CLINICAL CANCER RESEARCH, 2024, 30 (08) : 1582 - 1594
[48] Acquired resistance to gefitinib is associated with cancer stem-like phenotype and EMT in EGFR mutant lung adenocarcinoma.
Lim, Sun Min
Kim, Hyun Jung
Ban, Young Ho
Ha, Sang Jun
Cho, Byoung Chui
CANCER RESEARCH, 2013, 73 (08)
[49] ACQUIRED RESISTANCE IN NSCLC WITH EGFR MUTATION TREATED WITH TKI'S: SINGLE CENTER EXPERIENCE AND TREATMENT OUTCOME
Griesinger, Frank
Halbfass, Volker
Conradi, Imme
Hallas, Cora
Henke, R. P.
Falk, Markus
Tiemann, Markus
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S798 - S799
[50] Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI)
Goldberg, Sarah B.
Oxnard, Geoffrey R.
Digumarthy, Subba
Muzikansky, Alona
Jackman, David Michael
Lennes, Inga Tolin
Sequist, Lecia V.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →